Evidence map›Paper›PMID 36618131›Full record

ArticleJournal of family medicine and primary care2022

Evaluation of glycemic control among Type 2 diabetic patients in the first visit after COVID-19 lockdown, Prince Mansour Military Hospital, Taif, Saudi Arabia.

Jumanah A Alsaedi, Abdulaziz F Alfadhly

Abstract read
In one paragraph

Article in Journal of family medicine and primary care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jumanah A AlsaediDepartment of Family Medicine, Prince Mansour Military Hospital, Taif City, Kingdom of Saudi Arabia.
Abdulaziz F AlfadhlyConsultant Family Medicine/Diabetologist, Diabetic Center, Prince Mansour Military Hospital, Taif, Kingdom of Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The coronavirus disease (COVID-19) pandemic causes significant morbidities and mortalities. Lockdown is applied worldwide to counteract the spread of the disease. These circumstances limit diabetic patients from hospital visits and follow-ups. Objectives: To evaluate glycemic control for type 2 diabetic patients in the first visit after COVID-19 lockdown and to study the effect of COVID-19 lockdown on glycemic control. Methods: A cross-sectional study was conducted at Prince Mansour Military Hospital, Taif city, Western Saudi Arabia. It included type 2 diabetic patients of both genders aged over 20 years that were assigned to follow-up in the diabetic center. Data were collected from patients' medical records using a simple random technique. It included patients` gender, age group, body mass index, and three glycosylated hemoglobin (HbA1c) readings for each year (2018-2019) and one HbA1C reading upon the first visit after COVID-19 lockdown. HbA1c level was treated as a continuous variable. Results: The study included 420 diabetic patients. Females represented 51% of them, and more than a third (39.8%) were aged 60 years and over. The majority of them were either overweight (29.3%) or obese (61.2%). There was an increase in the overall level of HbA1c after curfew (8.72 ± 1.73) than before it (8.58 ± 1.72). However, the difference did not reach a statistically significant level, Conclusion: There was a relative increase in the level of HbA1c after the lockdown during COVID-19, indicating poorer glycemic control; this impact was more obvious among female and obese type 2 diabetic patients.

Indexed as

COVID-19HbA1c levelLockdownSaudi Arabia

Identifiers

PMID36618131
PMCPMC9810912

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.